Prestige Consumer Healthcare (NYSE:PBH) Upgraded to Buy by StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBHFree Report) from a hold rating to a buy rating in a report released on Saturday morning.

A number of other research firms have also recently commented on PBH. BMO Capital Markets decreased their target price on shares of Prestige Consumer Healthcare from $124.00 to $117.00 and set an outperform rating on the stock in a research report on Wednesday, November 15th. Royal Bank of Canada decreased their price objective on Prestige Consumer Healthcare from $110.00 to $103.00 and set a sector perform rating for the company in a research note on Wednesday, November 15th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $97.00.

View Our Latest Analysis on PBH

Prestige Consumer Healthcare Stock Down 0.9 %

PBH opened at $68.02 on Friday. Prestige Consumer Healthcare has a twelve month low of $55.96 and a twelve month high of $69.29. The company has a market cap of $3.38 billion, a PE ratio of -41.48, a price-to-earnings-growth ratio of 1.98 and a beta of 0.50. The company has a 50-day moving average price of $61.14 and a 200 day moving average price of $60.22. The company has a quick ratio of 1.92, a current ratio of 3.09 and a debt-to-equity ratio of 0.75.

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) last announced its quarterly earnings data on Thursday, February 8th. The company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.02. The firm had revenue of $282.74 million during the quarter, compared to analyst estimates of $280.25 million. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. Prestige Consumer Healthcare’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.04 earnings per share. Sell-side analysts expect that Prestige Consumer Healthcare will post 4.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 5,336 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $69.00, for a total transaction of $368,184.00. Following the completion of the sale, the senior vice president now owns 15,934 shares in the company, valued at approximately $1,099,446. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $25,000. Altshuler Shaham Ltd purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth approximately $27,000. Pacer Advisors Inc. grew its position in Prestige Consumer Healthcare by 85.7% during the fourth quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock valued at $27,000 after purchasing an additional 204 shares in the last quarter. Provence Wealth Management Group acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at about $26,000. Finally, Principal Securities Inc. acquired a new position in Prestige Consumer Healthcare during the 4th quarter worth $29,000. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Featured Stories

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.